Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1990-10-17
1992-09-22
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514459, 514466, 514519, 514521, 514528, 514529, 514533, 514548, A61K 31225, A61K 3135, A61K 3136, A61K 31275
Patent
active
051497107
ABSTRACT:
Compounds of formula (II) ##STR1## wherein R.sub.1 and R.sub.2 are each separately selected from hydrogen, alkyl, alkenyl and alkynyl groups having up to a maximum of four carbon atoms and being unsubstituted, and alkyl, alkenyl and alkynyl groups having up to a maximum of three carbon atoms and being substituted by one, or in the case of fluoro by one or more, substituents but with the proviso that when R.sub.1 is hydrogen then R.sub.2 is hydrogen or methyl, or R.sub.1 and R.sub.2 together constitute an ethylene bridging group, and R.sub.3 is a group which under physiological conditions undergoes elimination with the formation of a 3,5-dioxopiperazinyl ring, with the further proviso that the compound is in the meso or erythro configuration when each of R.sub.1 and R.sub.2 is the same or different unsubstituted or substituted alkyl, alkenyl or alkynyl group, and salts thereof with a physiologically acceptable inorganic or organic acid, are of value as prodrugs, particularly in the therapy of psoriasis.
REFERENCES:
patent: 3164580 (1965-03-01), Matson
patent: 3351658 (1967-09-01), Bersworth
patent: 3497535 (1970-10-01), Lennon
patent: 3941790 (1976-04-01), Creighton
patent: 4275063 (1981-10-01), Creighton
patent: 4432907 (1984-08-01), Wieder
Herman et al. "Comparison of the Effectiveness . . . " Cancer Research 45, 276-281, Jan. 1985.
Von Hoff et al. "Phase 1 Study of ICRF-187 . . . " Cancer Treatment Reports vol. 65, No. 3-4 Mar.-Apr. 1981.
Herman et al. "Biological Properties of ICRF-159 . . . " Advances in Pharmacology & Chemotherapy, vol. 19, pp. 249-291, (1982).
Creighton, Chem. Abstract, 93:197550 d(1980) Sinkulaa et al., Jour. of Pharmaceutical Sc. 1975 vol. 64, pp. 181-210.
Zhang et al., Acta Pharmaceutica Sinica, 1980 vol. 15, pp. 557-583 Abstract Only.
Ren et al., Abs. of Papers of the Ame. Chem. Soc. Aug. 1981, vol. 182, No. 18.
Houghton et al., Jour. of the Chem. Soc. Perkins Transactions I, 1982, pp. 2693-2696.
Creighton et al., Scientific Rep. of the Imperial Cancer Res. Fund for 1983-1984, Apr. 2, 1985.
Creighton et al., Abstract of the 14th International Congress of Chemotherapy, Kyoto, Japan (Jun. 23 to 28, 1985) No. S-10-1.
Cai et al., Poster Session of the 14th International Congress of Chemotherapy, Kyoto, Japan (Jun. 23-28 1985).
Creighton et al. "Recent Advances in Chemotherapy" (Proc. of the 14th International Congress of Chem), pp. 481-482.
Herman, E. H. et al. "Comparison of the Protective Effect of ICRF-187 . . . " Research Comm. in Chemical Pathology & Pharmacology, vol. 48, No. 1, Apr. 1985 pp. 39-55.
May, P. M. et al. "Metal Binding by Pharmaceuticals . . . " Agents and Actions, vol. 15, 3/4 (1984) pp. 448-453.
Creighton Andrew M.
Jeffery William A.
Goldberg Jerome D.
National Research Development Corporation
LandOfFree
Pharmaceutical compositions for treating psoriasis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for treating psoriasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for treating psoriasis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1068579